Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07454291) titled 'A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants' on March 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Endeavor Biomedicines, Inc.
Condition:
Idiopathic Pulmonary Fibrosis
Intervention:
Drug: taladegib
Drug: Nintedanib
Drug: Pirfenidone
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 2026
Target Sample Size: 57
Countries of Recruitment:
Austral...